| Year |
Citation |
Score |
| 2023 |
Lyles RDZ, Martinez MJ, Sherman B, Schürer S, Burnstein KL. Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens. Plos One. 18: e0287126. PMID 37815978 DOI: 10.1371/journal.pone.0287126 |
0.494 |
|
| 2023 |
Martinez MJ, Lyles RDZ, Peinetti N, Grunfeld AM, Burnstein KL. Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancer. Iscience. 26: 107681. PMID 37705955 DOI: 10.1016/j.isci.2023.107681 |
0.401 |
|
| 2022 |
Peinetti N, Bilusic M, Burnstein KL. Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy? The Journal of Clinical Investigation. 132. PMID 36453547 DOI: 10.1172/JCI165357 |
0.501 |
|
| 2022 |
Heidman LM, Peinetti N, Copello VA, Burnstein KL. Exploiting dependence of castration-resistant prostate cancer on the arginine vasopressin signaling axis by repurposing vaptans. Molecular Cancer Research : McR. PMID 35503085 DOI: 10.1158/1541-7786.MCR-21-0927 |
0.509 |
|
| 2022 |
Copello VA, Burnstein KL. The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor. Oncogene. 41: 2824-2832. PMID 35418689 DOI: 10.1038/s41388-022-02307-9 |
0.552 |
|
| 2019 |
Zhao N, Peacock SO, Lo CH, Heidman LM, Rice MA, Fahrenholtz CD, Greene AM, Magani F, Copello VA, Martinez MJ, Zhang Y, Daaka Y, Lynch CC, Burnstein KL. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. Science Translational Medicine. 11. PMID 31243151 DOI: 10.1126/Scitranslmed.Aaw4636 |
0.615 |
|
| 2019 |
Arora* H, Panara K, Kuchakulla M, Kulandavelu S, Burnstein KL, Schally AV, Hare JM, Ramasamy R. MP81-04 ALTERATIONS OF TUMOR MICROENVIRONMENT BY NITRIC OXIDE DONOR IMPEDES CASTRATION RESISTANT PROSTATE CANCER GROWTH Journal of Urology. 201. DOI: 10.1097/01.Ju.0000557423.80206.A6 |
0.489 |
|
| 2018 |
Arora H, Panara K, Kuchakulla M, Kulandavelu S, Burnstein KL, Schally AV, Hare JM, Ramasamy R. Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth. Proceedings of the National Academy of Sciences of the United States of America. PMID 30322928 DOI: 10.1073/Pnas.1812704115 |
0.401 |
|
| 2018 |
Birnbaum MD, Zhao N, Moorthy BT, Patel DM, Kryvenko ON, Heidman L, Kumar A, Morgan WM, Ban Y, Reis IM, Chen X, Gonzalgo ML, Jorda M, Burnstein KL, Zhang F. Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis. Oncogene. PMID 30177837 DOI: 10.1038/S41388-018-0462-2 |
0.584 |
|
| 2018 |
Magani F, Bray ER, Martinez MJ, Zhao N, Copello VA, Heidman L, Peacock SO, Wiley DJ, D'Urso G, Burnstein KL. Identification of an oncogenic network with prognostic and therapeutic value in prostate cancer. Molecular Systems Biology. 14: e8202. PMID 30108134 DOI: 10.15252/Msb.20188202 |
0.509 |
|
| 2018 |
Samaranayake GJ, Troccoli CI, Huynh MQ, Lyles RDZ, Kwon D, Ban Y, Chen SX, Jorda M, Burnstein K, Rai P. Abstract B032: Inappropriate AR reactivation-induced redox stress as a novel therapeutic target in castration-resistant prostate cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-B032 |
0.548 |
|
| 2018 |
Zhao N, Peacock S, Lo CH, Heidman L, Magani F, Rice M, Greene A, Zhang Y, Daaka Y, Lynch C, Burnstein K. Abstract A063: Preclinical evaluation of an arginine vasopressin receptor 1A (AVPR1A) antagonist in castration-resistant prostate cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-A063 |
0.621 |
|
| 2018 |
Magani F, Bray E, Martinez MJ, Copello V, Zhao N, Peacock S, Wiley D, D’urso G, Burnstein KL. Abstract A050: Integrated system-level analyses define an androgen receptor variant oncogenic network for advanced prostate cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-A050 |
0.555 |
|
| 2018 |
Birnbaum MD, Zhou N, Burnstein KL, Zhang F. Abstract A039: Arginyltransferase Ate1 reduction drives prostate cancer metastasis Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-A039 |
0.589 |
|
| 2018 |
Martinez MJ, Magani F, Bray ER, Copello V, Zhao N, Peacock S, Wiley DJ, D'Urso G, Burnstein KL. Abstract 1314: A prostate cancer androgen receptor variant gene network with prognostic and therapeutic value identified using integrated systems analyses Cancer Research. 78: 1314-1314. DOI: 10.1158/1538-7445.Am2018-1314 |
0.538 |
|
| 2018 |
Troccoli C, Lyles R, Samaranayake G, Huynh M, Kwon D, Ban Y, Chen S, Jorda M, Sharma N, Banerjee S, Burnstein K, Rai P. The ROS duality in castration-resistant prostate cancer emergence and progression Free Radical Biology and Medicine. 128: S75. DOI: 10.1016/J.Freeradbiomed.2018.10.163 |
0.524 |
|
| 2017 |
Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, et al. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology. PMID 29258679 DOI: 10.1016/J.Eururo.2017.11.038 |
0.599 |
|
| 2017 |
Samaranayake GJ, Troccoli CI, Huynh M, Lyles RDZ, Kage K, Win A, Lakshmanan V, Kwon D, Ban Y, Chen SX, Zarco ER, Jorda M, Burnstein KL, Rai P. Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer. Nature Communications. 8: 1204. PMID 29089489 DOI: 10.1038/S41467-017-01269-X |
0.599 |
|
| 2017 |
Magani F, Peacock SO, Rice MA, Martinez MJ, Greene AM, Magani PS, Lyles R, Weitz JR, Burnstein KL. Targeting AR Variant-coactivator Interactions to Exploit Prostate Cancer Vulnerabilities. Molecular Cancer Research : McR. PMID 28811363 DOI: 10.1158/1541-7786.Mcr-17-0280 |
0.504 |
|
| 2017 |
Magani F, Bray ER, Zhao N, Peacock S, Burnstein KL. Abstract 5545: Integrated system-level analyses of androgen receptor variant networks to identify novel prostate cancer-relevant genes Cancer Research. 77: 5545-5545. DOI: 10.1158/1538-7445.Am2017-5545 |
0.534 |
|
| 2017 |
Troccoli CI, Samaranayake GJ, Huynh MQ, Kage K, Kwon D, Ban Y, Chen XS, Zarco ER, Jorda M, Burnstein KL, Rai P. Abstract 5479: Redox stress as a therapeutic Achilles heel in castration-resistant prostate cancer Cancer Research. 77: 5479-5479. DOI: 10.1158/1538-7445.Am2017-5479 |
0.508 |
|
| 2017 |
Magani F, Bray E, Peacock S, Zhao N, Burnstein K. Integrated system-level analyses of androgen receptor variant networks to identify novel prostate cancer-relevant genes that serve as prognostic biomarkers Annals of Oncology. 28: v8. DOI: 10.1093/ANNONC/MDX361.025 |
0.436 |
|
| 2016 |
Udayakumar TS, Stoyanova R, Shareef MM, Mu Z, Philip S, Burnstein KL, Pollack A. Edelfosine Promotes Apoptosis in Androgen Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity. Molecular Cancer Therapeutics. PMID 26944919 DOI: 10.1158/1535-7163.Mct-15-0332 |
0.564 |
|
| 2016 |
Rice MA, Ishteiwy RA, Magani F, Udayakumar T, Reiner T, Yates TJ, Miller P, Perez-Stable C, Rai P, Verdun R, Dykxhoorn DM, Burnstein KL. The microRNA-23b/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related. Oncogene. PMID 26898757 DOI: 10.1038/Onc.2016.6 |
0.416 |
|
| 2014 |
Fahrenholtz CD, Greene AM, Beltran PJ, Burnstein KL. A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells. Oncotarget. 5: 9007-21. PMID 25344862 DOI: 10.18632/Oncotarget.2346 |
0.526 |
|
| 2014 |
Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, Pérez Tenorio G, ... ... Burnstein KL, et al. VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Research : Bcr. 16: R53. PMID 24886537 DOI: 10.1186/Bcr3664 |
0.401 |
|
| 2014 |
Jaganathan A, Chaurasia P, Xiao GQ, Philizaire M, Lv X, Yao S, Burnstein KL, Liu DP, Levine AC, Mujtaba S. Coactivator MYST1 regulates nuclear factor-κB and androgen receptor functions during proliferation of prostate cancer cells. Molecular Endocrinology (Baltimore, Md.). 28: 872-85. PMID 24702180 DOI: 10.1210/Me.2014-1055 |
0.589 |
|
| 2014 |
Fahrenholtz CD, Rick FG, Garcia MI, Zarandi M, Cai RZ, Block NL, Schally AV, Burnstein KL. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: 1084-9. PMID 24395797 DOI: 10.1073/Pnas.1323102111 |
0.603 |
|
| 2014 |
Rick FG, Fahrenholtz CD, Garcia MI, Block NL, Schally AV, Burnstein KL. Preclinical efficacy of growth hormone-releasing hormone antagonist MIA-602 for androgen-dependent and castration-resistant human prostate cancer. Journal of Clinical Oncology. 32: 221-221. DOI: 10.1200/Jco.2014.32.4_Suppl.221 |
0.565 |
|
| 2014 |
Rice MA, Ishteiwy R, Udayakumar T, Dykxhoorn D, Burnstein KL. Abstract 1467: The miR-23b/-27b cluster decreases metastasis of aggressive prostate cancer Cancer Research. 74: 1467-1467. DOI: 10.1158/1538-7445.Am2014-1467 |
0.401 |
|
| 2013 |
Fahrenholtz CD, Beltran PJ, Burnstein KL. Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts. Molecular Cancer Therapeutics. 12: 394-404. PMID 23348048 DOI: 10.1158/1535-7163.Mct-12-0648 |
0.574 |
|
| 2013 |
Wu F, Peacock SO, Rao S, Lemmon SK, Burnstein KL. Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth. The Journal of Biological Chemistry. 288: 5463-74. PMID 23281476 DOI: 10.1074/Jbc.M112.390963 |
0.774 |
|
| 2013 |
Peacock S, Fahrenholtz CD, Burnstein KL. Abstract 1069: Vav3 enhances androgen receptor splice variant activity and is critical for castration resistant prostate cancer growth and survival. Cancer Research. 73: 1069-1069. DOI: 10.1158/1538-7445.Am2013-1069 |
0.62 |
|
| 2012 |
Ishteiwy RA, Ward TM, Dykxhoorn DM, Burnstein KL. The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells. Plos One. 7: e52106. PMID 23300597 DOI: 10.1371/Journal.Pone.0052106 |
0.426 |
|
| 2012 |
Peacock SO, Fahrenholtz CD, Burnstein KL. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival. Molecular Endocrinology (Baltimore, Md.). 26: 1967-79. PMID 23023561 DOI: 10.1210/Me.2012-1165 |
0.607 |
|
| 2012 |
Rao S, Lyons LS, Fahrenholtz CD, Wu F, Farooq A, Balkan W, Burnstein KL. A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer. Oncogene. 31: 716-27. PMID 21765461 DOI: 10.1038/Onc.2011.273 |
0.758 |
|
| 2012 |
Peacock S, Fahrenholtz C, Burnstein KL. Abstract 2148: Exploitation of androgen receptor splice variant signaling by guanine nucleotide exchange factor Vav3 in castration resistant prostate cancer Cancer Research. 72: 2148-2148. DOI: 10.1158/1538-7445.Am2012-2148 |
0.553 |
|
| 2011 |
Rosenblatt AE, Garcia MI, Lyons L, Xie Y, Maiorino C, Désiré L, Slingerland J, Burnstein KL. Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer. Endocrine-Related Cancer. 18: 207-19. PMID 21118977 DOI: 10.1677/Erc-10-0049 |
0.417 |
|
| 2011 |
Fahrenholtz CD, Beltran PJ, Calzone FJ, Burnstein KL. Abstract C55: Ganitumab (AMG 479) inhibits the development and progression of castration-resistant VCaP human prostate cancer xenografts. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C55 |
0.598 |
|
| 2010 |
Flores O, Burnstein KL. GADD45gamma: a new vitamin D-regulated gene that is antiproliferative in prostate cancer cells. Endocrinology. 151: 4654-64. PMID 20739400 DOI: 10.1210/En.2010-0434 |
0.785 |
|
| 2010 |
Flores O, Wang Z, Knudsen KE, Burnstein KL. Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology. 151: 896-908. PMID 20147522 DOI: 10.1210/En.2009-1116 |
0.732 |
|
| 2009 |
Rosenblatt AE, Burnstein KL. Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic. Molecular Endocrinology (Baltimore, Md.). 23: 412-21. PMID 19131511 DOI: 10.1210/Me.2008-0235 |
0.606 |
|
| 2009 |
Lee JG, Zheng R, McCafferty-Cepero JM, Burnstein KL, Nanus DM, Shen R. Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells. Molecular Carcinogenesis. 48: 141-9. PMID 18623111 DOI: 10.1002/Mc.20462 |
0.451 |
|
| 2008 |
Lyons LS, Rao S, Balkan W, Faysal J, Maiorino CA, Burnstein KL. Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer. Molecular Endocrinology (Baltimore, Md.). 22: 597-608. PMID 18079321 DOI: 10.1210/Me.2007-0158 |
0.768 |
|
| 2007 |
Gomez LA, de Las Pozas A, Reiner T, Burnstein K, Perez-Stable C. Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy. Molecular Cancer Therapeutics. 6: 1534-43. PMID 17513602 DOI: 10.1158/1535-7163.Mct-06-0727 |
0.512 |
|
| 2006 |
Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, Wilson EM, McDonnell DP, Cidlowski JA. International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacological Reviews. 58: 782-97. PMID 17132855 DOI: 10.1124/Pr.58.4.9 |
0.344 |
|
| 2006 |
Lyons LS, Burnstein KL. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Molecular Endocrinology (Baltimore, Md.). 20: 1061-72. PMID 16384856 DOI: 10.1210/Me.2005-0346 |
0.616 |
|
| 2005 |
Burnstein KL. Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. Journal of Cellular Biochemistry. 95: 657-69. PMID 15861399 DOI: 10.1002/Jcb.20460 |
0.612 |
|
| 2005 |
Balkan W, Burnstein KL, Schiller PC, Perez-Stable C, D'Ippolito G, Howard GA, Roos BA. Androgen-induced mineralization by MC3T3-E1 osteoblastic cells reveals a critical window of hormone responsiveness. Biochemical and Biophysical Research Communications. 328: 783-9. PMID 15694414 DOI: 10.1016/J.Bbrc.2004.12.090 |
0.406 |
|
| 2004 |
Knight-Krajewski S, Welsh CF, Liu Y, Lyons LS, Faysal JM, Yang ES, Burnstein KL. Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells. Oncogene. 23: 5513-22. PMID 15077174 DOI: 10.1038/Sj.Onc.1207708 |
0.719 |
|
| 2004 |
Kizu R, Otsuki N, Kishida Y, Toriba A, Mizokami A, Burnstein KL, Klinge CM, Hayakawai K. A new luciferase reporter gene assay for the detection of androgenic and antiandrogenic effects based on a human prostate specific antigen promoter and PC3/AR human prostate cancer cells. Analytical Sciences : the International Journal of the Japan Society For Analytical Chemistry. 20: 55-9. PMID 14753257 DOI: 10.2116/Analsci.20.55 |
0.569 |
|
| 2004 |
Okamura K, Kizu R, Toriba A, Murahashi T, Mizokami A, Burnstein KL, Klinge CM, Hayakawa K. Antiandrogenic activity of extracts of diesel exhaust particles emitted from diesel-engine truck under different engine loads and speeds. Toxicology. 195: 243-54. PMID 14751679 DOI: 10.1016/J.Tox.2003.10.011 |
0.407 |
|
| 2004 |
Schwartz GG, Eads D, Rao A, Cramer SD, Willingham MC, Chen TC, Jamieson DP, Wang L, Burnstein KL, Holick MF, Koumenis C. Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis. 25: 1015-26. PMID 14742320 DOI: 10.1093/Carcin/Bgh086 |
0.457 |
|
| 2004 |
Okamura K, Kizu R, Hayakawa K, Toriba A, Mizokami A, Burnstein KL, Klinge CM, Kato S. VARIATION IN THE ANTIANDROGENIC ACTIVITY OF DIESEL EXHAUST PARTICULATES EMITTED UNDER DIFFERENT ENGINE LOADS Polycyclic Aromatic Compounds. 24: 743-757. DOI: 10.1080/10406630490472518 |
0.351 |
|
| 2003 |
Kizu R, Okamura K, Toriba A, Mizokami A, Burnstein KL, Klinge CM, Hayakawa K. Antiandrogenic activities of diesel exhaust particle extracts in PC3/AR human prostate carcinoma cells. Toxicological Sciences : An Official Journal of the Society of Toxicology. 76: 299-309. PMID 12970580 DOI: 10.1093/Toxsci/Kfg230 |
0.521 |
|
| 2003 |
Yang ES, Burnstein KL. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. The Journal of Biological Chemistry. 278: 46862-8. PMID 12954644 DOI: 10.1074/Jbc.M306340200 |
0.648 |
|
| 2003 |
Chen TC, Holick MF, Lokeshwar BL, Burnstein KL, Schwartz GG. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer Recent Results in Cancer Research. Fortschritte Der Krebsforschung. ProgrèS Dans Les Recherches Sur Le Cancer. 164: 273-288. PMID 12899529 DOI: 10.1007/978-3-642-55580-0_20 |
0.455 |
|
| 2003 |
Kizu R, Okamura K, Toriba A, Kakishima H, Mizokami A, Burnstein KL, Hayakawa K. A role of aryl hydrocarbon receptor in the antiandrogenic effects of polycyclic aromatic hydrocarbons in LNCaP human prostate carcinoma cells. Archives of Toxicology. 77: 335-43. PMID 12799773 DOI: 10.1007/S00204-003-0454-Y |
0.503 |
|
| 2002 |
Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES, Holick MF, Chen TC. 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. The Journal of Steroid Biochemistry and Molecular Biology. 81: 135-40. PMID 12137802 DOI: 10.1016/S0960-0760(02)00053-5 |
0.529 |
|
| 2002 |
Yang ES, Maiorino CA, Roos BA, Knight SR, Burnstein KL. Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer. Molecular and Cellular Endocrinology. 186: 69-79. PMID 11850123 DOI: 10.1016/S0303-7207(01)00671-2 |
0.756 |
|
| 2001 |
Tekur S, Lau KM, Long J, Burnstein K, Ho SM. Expression of RFG/ELE1alpha/ARA70 in normal and malignant prostatic epithelial cell cultures and lines: regulation by methylation and sex steroids. Molecular Carcinogenesis. 30: 1-13. PMID 11255259 DOI: 10.1002/1098-2744(200101)30:1<1::Aid-Mc1008>3.0.Co;2-X |
0.601 |
|
| 2001 |
Grad JM, Lyons LS, Robins DM, Burnstein KL. The androgen receptor (AR) amino-terminus imposes androgen-specific regulation of AR gene expression via an exonic enhancer. Endocrinology. 142: 1107-16. PMID 11181525 DOI: 10.1210/Endo.142.3.8049 |
0.476 |
|
| 2000 |
Qadan LR, Perez-Stable CM, Schwall RH, Burnstein KL, Ostenson RC, Howard GA, Roos BA. Hepatocyte growth factor and vitamin D cooperatively inhibit androgen-unresponsive prostate cancer cell lines Endocrinology. 141: 2567-2573. PMID 10875259 DOI: 10.1210/Endo.141.7.7546 |
0.618 |
|
| 2000 |
Shen R, Sumitomo M, Dai J, Harris A, Kaminetzky D, Gao M, Burnstein KL, Nanus DM. Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase Endocrinology. 141: 1699-1704. PMID 10803579 DOI: 10.1210/Endo.141.5.7463 |
0.57 |
|
| 2000 |
Gkonos PJ, Guo F, Burnstein KL. Type 1 vasoactive intestinal peptide receptor expression in PC3/AR cells is evidence of prostate epithelial differentiation. The Prostate. 42: 137-44. PMID 10617871 DOI: 10.1002/(Sici)1097-0045(20000201)42:2<137::Aid-Pros8>3.0.Co;2-U |
0.558 |
|
| 2000 |
Gkonos PJ, Guo F, Burnstein KL. Type 1 vasoactive intestinal peptide receptor expression in PC3/AR cells is evidence of prostate epithelial differentiationThe authors have no financial arrangements with any companies whose products are mentioned in this manuscript or with any competitors of these companies. The Prostate. 42: 137. DOI: 10.1002/(Sici)1097-0045(20000201)42:2<137::Aid-Pros8>3.3.Co;2-L |
0.474 |
|
| 1999 |
Grad JM, Dai JL, Wu S, Burnstein KL. Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. Molecular Endocrinology (Baltimore, Md.). 13: 1896-911. PMID 10551783 DOI: 10.1210/Mend.13.11.0369 |
0.508 |
|
| 1998 |
Zhuang SH, Burnstein KL. Antiproliferative Effect of 1α,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation. Endocrinology. 139: 1197-1207. PMID 28200515 DOI: 10.1210/Endo.139.3.5770 |
0.608 |
|
| 1997 |
Czerwiec FS, Liaw JJ, Liu SB, Perez-Stable C, Grumbles R, Howard GA, Roos BA, Burnstein KL. Absence of androgen-mediated transcriptional effects in osteoblastic cells despite presence of androgen receptors Bone. 21: 49-56. PMID 9213007 DOI: 10.1016/S8756-3282(97)00079-3 |
0.495 |
|
| 1997 |
Zhuang SH, Schwartz GG, Cameron D, Burnstein KL. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines Molecular and Cellular Endocrinology. 126: 83-90. PMID 9027366 DOI: 10.1016/S0303-7207(96)03974-3 |
0.535 |
|
| 1997 |
Dai JL, Burnstein KL. Two androgen response elements in the androgen receptor coding region are required for cell-specific up-regulation of receptor messenger RNA. Molecular Endocrinology (Baltimore, Md.). 10: 1582-94. PMID 8961268 DOI: 10.1210/Mend.10.12.8961268 |
0.494 |
|
| 1997 |
Dai JL, Maiorino CA, Gkonos PJ, Burnstein KL. Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells. Steroids. 61: 531-9. PMID 8883219 DOI: 10.1016/S0039-128X(96)00086-4 |
0.611 |
|
| 1995 |
Burnstein KL, Maiorino CA, Dai JL, Cameron DJ. Androgen and glucocorticoid regulation of androgen receptor cDNA expression. Molecular and Cellular Endocrinology. 115: 177-86. PMID 8824893 DOI: 10.1016/0303-7207(95)03688-1 |
0.493 |
|
| 1995 |
Jewell CM, Webster JC, Burnstein KL, Sar M, Bodwell JE, Cidlowski JA. Immunocytochemical analysis of hormone mediated nuclear translocation of wild type and mutant glucocorticoid receptors. The Journal of Steroid Biochemistry and Molecular Biology. 55: 135-46. PMID 7495692 DOI: 10.1016/0960-0760(95)00174-X |
0.353 |
|
| 1992 |
Burnstein KL, Cidlowski JA. The down side of glucocorticoid receptor regulation. Molecular and Cellular Endocrinology. 83: C1-8. PMID 1551466 DOI: 10.1016/0303-7207(92)90187-B |
0.332 |
|
| 1991 |
Burnstein KL, Bellingham DL, Jewell CM, Powell-Oliver FE, Cidlowski JA. Autoregulation of glucocorticoid receptor gene expression. Steroids. 56: 52-8. PMID 2020978 DOI: 10.1016/0039-128X(91)90124-E |
0.371 |
|
| 1989 |
Burnstein KL, Cidlowski JA. Regulation of gene expression by glucocorticoids. Annual Review of Physiology. 51: 683-99. PMID 2540703 DOI: 10.1146/Annurev.Ph.51.030189.003343 |
0.39 |
|
| Show low-probability matches. |